Literature DB >> 10090774

Molybdate inhibits hsp90, induces structural changes in its C-terminal domain, and alters its interactions with substrates.

S D Hartson1, V Thulasiraman, W Huang, L Whitesell, R L Matts.   

Abstract

To examine the biochemical mechanism by which hsp90 exerts its essential positive function on certain signal transduction proteins, we characterized the effects of molybdate and geldanamycin on hsp90 function and structure. Molybdate inhibited hsp90-mediated p56lck biogenesis and luciferase renaturation while enforcing salt-stable interactions with these substrates. Molybdate also reduced the amount of free hsp90 present in cell lysates, inhibited hsp90's ability to bind geldanamycin, and induced resistance to proteolysis at a specific region within the C-terminal domain of hsp90. In contrast, the hsp90 inhibitor geldanamycin prevented hsp90 from assuming natural or molybdate-induced conformations that allow salt-stable interactions with substrates. When these compounds were applied sequentially, the order of addition determined the effects observed, indicating that these agents had opposing effects on hsp90. We conclude that a specific region within the C-terminal domain of hsp90 (near residue 600) determines the mode by which hsp90 interacts with substrates and that the ability of hsp90 to cycle between alternative modes of interaction is obligatory for hsp90 function.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10090774     DOI: 10.1021/bi983027s

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  21 in total

1.  Alternative approaches to Hsp90 modulation for the treatment of cancer.

Authors:  Jessica A Hall; Leah K Forsberg; Brian S J Blagg
Journal:  Future Med Chem       Date:  2014-09       Impact factor: 3.808

2.  High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase.

Authors:  Lakshmi Galam; M Kyle Hadden; Zeqiang Ma; Qi-Zhuang Ye; Bo-Geon Yun; Brian S J Blagg; Robert L Matts
Journal:  Bioorg Med Chem       Date:  2007-01-04       Impact factor: 3.641

3.  An acetylation site in the middle domain of Hsp90 regulates chaperone function.

Authors:  Bradley T Scroggins; Kenneth Robzyk; Dongxia Wang; Monica G Marcu; Shinji Tsutsumi; Kristin Beebe; Robert J Cotter; Sara Felts; David Toft; Larry Karnitz; Neal Rosen; Len Neckers
Journal:  Mol Cell       Date:  2007-01-12       Impact factor: 17.970

4.  Gambogic acid, a natural product inhibitor of Hsp90.

Authors:  Jason Davenport; Jacob R Manjarrez; Laura Peterson; Brian Krumm; Brian S J Blagg; Robert L Matts
Journal:  J Nat Prod       Date:  2011-04-12       Impact factor: 4.050

5.  A systematic protocol for the characterization of Hsp90 modulators.

Authors:  Robert L Matts; Gary E L Brandt; Yuanming Lu; Anshuman Dixit; Mehdi Mollapour; Suiquan Wang; Alison C Donnelly; Leonard Neckers; Gennady Verkhivker; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2010-10-19       Impact factor: 3.641

6.  Heat shock protein 90 and the nuclear transport of progesterone receptor.

Authors:  M Haverinen; S Passinen; H Syvälä; S Pasanen; T Manninen; P Tuohimaa; T Ylikomi
Journal:  Cell Stress Chaperones       Date:  2001-07       Impact factor: 3.667

Review 7.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Authors:  Alison Donnelly; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

8.  Hsp90-Sgt1 and Skp1 target human Mis12 complexes to ensure efficient formation of kinetochore-microtubule binding sites.

Authors:  Alexander E Davies; Kenneth B Kaplan
Journal:  J Cell Biol       Date:  2010-04-19       Impact factor: 10.539

9.  Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir.

Authors:  Joong Sup Shim; Rajini Rao; Kristin Beebe; Len Neckers; Inkyu Han; Rita Nahta; Jun O Liu
Journal:  J Natl Cancer Inst       Date:  2012-10-05       Impact factor: 13.506

Review 10.  Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.

Authors:  Gary E L Brandt; Brian S J Blagg
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.